Aridis Pharmaceuticals Inc (NASDAQ:ARDS)
| 1.10 Delayed Data As of May 20 |  +0.08 / +7.84%Today’s Change | 0.88 Today|||52-Week Range 7.72 | -52.79% Year-to-Date |
Latest ARDS News | Press Releases
| Aridis Pharmaceuticals (ARDS) Reports Q1 Loss, Lags Revenue Estimates May 16 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 1.02 |
| Today’s open | 1.01 |
| Day’s range | 0.95 - 1.10 |
| Volume | 270 |
| Average volume (3 months) | 1,026,758 |
| Market cap | $16.5M |
Data as of 3:52pm ET, 05/20/2022
Growth & Valuation
| Earnings growth (last year) | -54.71% |
| Earnings growth (this year) | +61.43% |
| Earnings growth (next 5 years) | +51.90% |
| Revenue growth (last year) | +53.50% |
| P/E ratio | NM |
| Price/Sales | 18.66 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| QLGNQualigen Therapeutic... | -0.00 | -0.63% |
| PULMPulmatrix Inc | -0.16 | -3.09% |
| ---- | ||
| --ValiRx PLC | 0.00 | 0.00% |
Data as of 3:52pm ET, 05/20/2022
Financials
| Next reporting date | August 16, 2022 |
| EPS forecast (this quarter) | -$0.48 |
| Annual revenue (last year) | $1.5M |
| Annual profit (last year) | -$42.2M |
| Net profit margin | -2,748.73% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Los Gatos, California |
Forecasts
